Table 2 Baseline characteristics in CDARS before propensity score weighting
Warfarin + PPI | Warfarin only | DOAC + PPI | DOAC only | |
|---|---|---|---|---|
Total | 8491 | 8364 | 14,714 | 16,648 |
Age at index date | ||||
Median (IQR) | 74.6 (64.7–82.1) | 72.1 (62.9–80.1) | 78.9 (70.4–84.8) | 76.2 (67.7–82.8) |
Min, max | 18.9, 101.3 | 21.0, 101.6 | 26.8, 109.8 | 18.6, 104.4 |
Age group | ||||
18– < 40 | 75 (0.9) | 125 (1.5) | 38 (0.3) | 72 (0.4) |
40– < 50 | 271 (3.2) | 303 (3.6) | 162 (1.1) | 264 (1.6) |
50– < 60 | 919 (10.8) | 1101 (13.2) | 802 (5.5) | 1186 (7.1) |
60– < 70 | 1987 (23.4) | 2202 (26.3) | 2554 (17.4) | 3733 (22.4) |
70– < 80 | 2485 (29.3) | 2504 (29.9) | 4482 (30.5) | 5458 (32.8) |
80+ | 2754 (32.4) | 2129 (25.5) | 6676 (45.4) | 5935 (35.6) |
Male sex | 4546 (53.5) | 4442 (53.1) | 7248 (49.3) | 8348 (50.1) |
Calendar year at cohort entry | ||||
2011 | 610 (7.2) | 1139 (13.6) | 126 (0.9) | 364 (2.2) |
2012 | 673 (7.9) | 1158 (13.8) | 261 (1.8) | 686 (4.1) |
2013 | 813 (9.6) | 1116 (13.3) | 490 (3.3) | 975 (5.9) |
2014 | 999 (11.8) | 1108 (13.2) | 818 (5.6) | 1259 (7.6) |
2015 | 1148 (13.5) | 1000 (12.0) | 1361 (9.2) | 1671 (10.0) |
2016 | 1188 (14.0) | 858 (10.3) | 1821 (12.4) | 2091 (12.6) |
2017 | 1133 (13.3) | 752 (9.0) | 2549 (17.3) | 2580 (15.5) |
2018 | 1073 (12.6) | 694 (8.3) | 3036 (20.6) | 3031 (18.2) |
2019 | 854 (10.1) | 539 (6.4) | 4252 (28.9) | 3991 (24.0) |
Polypharmacy (≥5 drugs) | 8134 (95.8) | 6696 (80.1) | 13,743 (93.4) | 13,114 (78.8) |
Medical history | ||||
Alcohol-related liver disease | 234 (2.8) | 131 (1.6) | 280 (1.9) | 231 (1.4) |
Any bleeding | 2158 (25.4) | 1128 (13.5) | 3109 (21.1) | 2200 (13.2) |
Chronic kidney disease | 803 (9.5) | 346 (4.1) | 365 (2.5) | 233 (1.4) |
COPD | 787 (9.3) | 523 (6.3) | 1286 (8.7) | 948 (5.7) |
Diabetes | 2213 (26.1) | 1451 (17.3) | 3170 (21.5) | 2831 (17.0) |
Heart failure | 3043 (35.8) | 1599 (19.1) | 3242 (22.0) | 2236 (13.4) |
Hypertension | 4137 (48.7) | 3117 (37.3) | 7299 (49.6) | 6800 (40.8) |
Ischaemic heart disease | 2493 (29.4) | 1149 (13.7) | 3863 (26.3) | 1976 (11.9) |
Peripheral arterial disease | 166 (2.0) | 58 (0.7) | 156 (1.1) | 86 (0.5) |
Peptic ulcer | 1216 (14.3) | 548 (6.6) | 1879 (12.8) | 971 (5.8) |
Stroke/TIA | 1168 (13.8) | 838 (10.0) | 1963 (13.3) | 1648 (9.9) |
Venous thromboembolism | 618 (7.3) | 331 (4.0) | 266 (1.8) | 130 (0.8) |
Medication use in the past 3 months | ||||
ACEI/ARBs | 4507 (53.1) | 3682 (44.0) | 7594 (51.6) | 7369 (44.3) |
Anticonvulsant | 1040 (12.2) | 411 (4.9) | 1531 (10.4) | 867 (5.2) |
Antidepressant | 501 (5.9) | 336 (4.0) | 963 (6.5) | 742 (4.5) |
Antiplatelet | 1361 (16.0) | 482 (5.8) | 2513 (17.1) | 788 (4.7) |
Aspirin | 4712 (55.5) | 5153 (61.6) | 8579 (58.3) | 9114 (54.7) |
Beta-blockers | 5146 (60.6) | 4801 (57.4) | 9050 (61.5) | 10,104 (60.7) |
CCBs | 4274 (50.3) | 4443 (53.1) | 8055 (54.7) | 9734 (58.5) |
Macrolides | 423 (5.0) | 250 (3.0) | 494 (3.4) | 315 (1.9) |
NSAIDs | 779 (9.2) | 434 (5.2) | 1299 (8.8) | 790 (4.7) |
Oestrogen/oestrogen like drugs | 10 (0.1) | 9 (0.1) | 21 (0.1) | 20 (0.1) |
Oral corticosteroids | 1110 (13.1) | 558 (6.7) | 1663 (11.3) | 957 (5.7) |
Statins | 4566 (53.8) | 3527 (42.2) | 9305 (63.2) | 8498 (51.0) |
